Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion type Assertion NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_head.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion description "[In addition, the ERK1/2-binding IQGAP1 WW domain peptide disrupted IQGAP1-ERK1/2 interactions, inhibited RAS- and RAF-driven tumorigenesis, bypassed acquired resistance to the BRAF inhibitor vemurafenib (PLX-4032) and acted as a systemically deliverable therapeutic to significantly increase the lifespan of tumor-bearing mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_provenance.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion evidence source_evidence_literature NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_provenance.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion SIO_000772 23603816 NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_provenance.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion wasDerivedFrom befree-20150227 NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_provenance.
- NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_assertion wasGeneratedBy ECO_0000203 NP865311.RA89-ZxsvqrUAmZzverYoNJHiJ_xP0fGvKDDDKH_AFQZ4130_provenance.